Some blood parameters can be measured non-invasively with infrared light. Using this feature, researchers from the ICFO Institute have developed biomarkers of endothelial and microvascular health for coronavirus patients admitted to the ICU. The device has begun testing on patients’ forearms in Tací Parc Taulí Hospital and other medical centers in Spain and the United States.
When childbirth started in Spain, a team of researchers from Spain Institute of Photonics Science (ICFO) People from Barcelona participated in international efforts to fight the COVID-19 pandemic.
Under the guidance of Professor ICREA Turgut Durduran, These experts in the field of diffuse optics held a remote meeting and proposed possible ideas based on photonic technology, which may help the treatment of coronavirus patients.
They quickly tried to adapt to commercial equipment Near infrared spectroscopy (in English, Near infrared spectrometer Or NIRS), and equipped with a special algorithm to assess the patient’s microvascular status, because the health of the smallest blood vessels plays a key role in the development of the disease.
Durduran said: “During delivery, this project worked very fast.” Taoli Park HospitalIn Sabadell, led by a doctor Jaume Mesquida.
They jointly developed a set of hypotheses and protocols designed to test endothelial and microvascular dysfunction in patients with COVID-19. This collaboration is made possible by biophotonic technology that uses near-infrared light to measure oxygen saturation, volume, and blood flow.
The first device was sent to Taulí Hospital in March and tested on COVID-19 patients.Soon thereafter, interest in such cooperation led to the establishment of an international consortium called HEMOCOVID-19.
Its members use the microvasculature in the muscles around the forearm to respond to prolonged arterial block (blood pressure is measured by a device similar to an inflatable tourniquet). Endothelial and microvascular health biomarkers.
This is anNon-intrusive portable device with built-in battery No cables are required, and measurements can be performed in the entire patient in the entire intensive care unit.
The goal is to provide tools to assist clinicians in selecting patients and to guide the development of treatments aimed at improving endothelial function and function. Personalized rescue therapy, Plays a vital role in the management of critically ill patients.
As Dr. Mesquida pointed out: “This is not onlyRisk stratification of COVID-19 patients [debido a las complicaciones relacionadas con el síndrome de estrés respiratorio agudo], Can also be used as Assess the efficacy of potential new treatments For disease”.
“As of today-he continues-we have no other parameters at the bedside to monitor endothelial function, and it may be necessary to force the use of this technology to evaluate therapies for microcirculation, which seems very important in COVID -19. These measures are the most important. May be useful in other people with underlying endothelial function changes or inflammatory diseases, such as Septic shock patients“.
The initial results encouraged the consortium.The next step will involve the development of next-generation technologies to Improve accuracy and expand clinical relevance.The consortium continues to grow and currently consists of Ten partners from four countries: Spain (Spain that has joined HospitalClínic and Hospital del Mar), the United States, Brazil and Mexico.
HEMOCOVID-19 is coordinated by ICFO (Marco Pagliazzi, Lorenzo Cortese, Umut Karadeniz, Ariadna Martinez and Martina Giovannella also participated in the meeting) and is open to new members.